Biotech Médical/santé/bien-être/medtech

Description du projet

SPINOVIT is a spin off from UCLouvain and proposes a robust biomarker of the endothelial dysfunction for the detection of the early stages of any cardiovascular disease. Cardiovascular diseases are the first cause of mortality in the world. They have a major socio-economic impact as they can also result from different pathologies (metabolic syndrome, sleep apnea,…) or consumption of drugs (anti-cancer drugs, contraceptive pills,…). Vascular atherosclerosis is the underlying pathogenic process driven by risk factors such as smoking, obesity, hypertension, diabetes and dyslipidemia. There is now a wide consensus that endothelial dysfunction is the early step leading to atherosclerosis. However, endothelial dysfunction at its early stages is difficult to detect non-invasively. Such a biomarker currently does not exist. Some diagnostic kits are available but do not focus on the endothelial dysfunction. Our kit consists in a patented syringe, a hands-off secured shipment and a patented measurement of our biomarker by an innovative technology (electronic paramagnetic resonance spectroscopy) setup in our laboratory. Health care is at the heart of our team who is composed of scientists (engineers, biologists, physicists) and physicians. The SPINOVIT kit will allow a better prevention against the cardiovascular diseases.

Problématique abordée par le projet

Solution(s) offerte(s) par le projet

    Besoin(s) du projet

    • Mentoring/Parrainage (présenter le projet à des experts / entreprises)
    • Financement

    Forum(s) au(x)quel(s) le projet a participé